Expression and functions of transmembrane mucin MUC13 in ovarian cancer.

MUC13, a transmembrane mucin, is normally expressed in gastrointestinal and airway epithelium. Its aberrant expression has been correlated with gastric colon and cancer. However, the expression and functions of MUC13 in ovarian cancer are unknown. In the present study, the expression profile and functions of MUC13 were analyzed to elucidate its potential role in ovarian cancer diagnosis and pathogenesis. A recently generated monoclonal antibody (clone PPZ0020) was used to determine the expression profile of MUC13 by immunohistochemistry using ovarian cancer tissue microarrays and 56 additional epithelial ovarian cancer (EOC) samples. The expression of MUC13 was significantly (P < 0.005) higher in cancer samples compared with the normal ovary/benign tissues. Among all ovarian cancer types, MUC13 expression was specifically present in EOC. For the functional analyses, a full-length MUC13 gene cloned in pcDNA3.1 was expressed in a MUC13 null ovarian cancer cell line, SKOV-3. Here, we show that the exogenous MUC13 expression induced morphologic changes, including scattering of cells. These changes were abrogated through c-Jun NH(2) kinase (JNK) chemical inhibitor (SP600125) or JNK2 siRNA. Additionally, a marked reduction in cell-cell adhesion and significant (P < 0.05) increases in cell motility, proliferation, and tumorigenesis in a xenograft mouse model system were observed upon exogenous MUC13 expression. These cellular characteristics were correlated with up-regulation of HER2, p21-activated kinase 1, and p38 protein expression. Our findings show the aberrant expression of MUC13 in ovarian cancer and that its expression alters the cellular characteristics of SKOV-3 cells. This implies a significant role of MUC13 in ovarian cancer.

[1]  Y. Lio,et al.  Combined Staining of TAG-72, MUC1, and CA125 Improves Labeling Sensitivity in Ovarian Cancer , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  M. Copin,et al.  MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms , 2007, Oncogene.

[3]  Lynette M. Smith,et al.  Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) , 2006, Modern Pathology.

[4]  B. Leggett,et al.  The MUC13 cell surface mucin is highly expressed by human colorectal carcinomas. , 2006, Human pathology.

[5]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[6]  H. Aburatani,et al.  Overexpression of MUC13 is associated with intestinal‐type gastric cancer , 2005, Cancer science.

[7]  C. J. Barnes,et al.  p21-Activated Kinase 1 Regulates Microtubule Dynamics by Phosphorylating Tubulin Cofactor B , 2005, Molecular and Cellular Biology.

[8]  P. Rao,et al.  E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. , 2005, Cancer research.

[9]  L. Packer,et al.  Expression of the cell surface mucin gene family in adenocarcinomas. , 2004, International journal of oncology.

[10]  J. Meza,et al.  Inhibition of MUC4 Expression Suppresses Pancreatic Tumor Cell Growth and Metastasis , 2004, Cancer Research.

[11]  K. Carraway,et al.  Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis. , 2002, The Biochemical journal.

[12]  T. Stossel,et al.  Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1 , 2002, Nature Cell Biology.

[13]  R. Ozols.  Update on the management of ovarian cancer. , 2002, Cancer journal.

[14]  U. Menon.  Ovarian cancer screening , 2002, Canadian Medical Association Journal.

[15]  J. Feldner,et al.  Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. , 2002, Experimental cell research.

[16]  H. Friess,et al.  Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Batra,et al.  Structural organization and classification of the human mucin genes. , 2001, Frontiers in bioscience : a journal and virtual library.

[19]  G. Sutherland,et al.  MUC13, a Novel Human Cell Surface Mucin Expressed by Epithelial and Hemopoietic Cells* , 2001, The Journal of Biological Chemistry.

[20]  M. Hollingsworth,et al.  Identification of MUC1 proteolytic cleavage sites in vivo. , 2001, Biochemical and biophysical research communications.

[21]  M. Hung,et al.  Overexpression of ErbB2 in cancer and ErbB2-targeting strategies , 2000, Oncogene.

[22]  H. Ji,et al.  C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines , 2000, Oncogene.

[23]  R. Dodge,et al.  Mucin gene expression in ovarian cancers. , 1998, Cancer research.

[24]  J. Mendelsohn,et al.  Heregulin Regulates Cytoskeletal Reorganization and Cell Migration through the p21-activated Kinase-1 via Phosphatidylinositol-3 Kinase* , 1998, The Journal of Biological Chemistry.

[25]  S. Mok,et al.  The biology of ovarian cancer. , 1998, Seminars in oncology.

[26]  N. Kohno,et al.  Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. , 1998, Cancer research.

[27]  C. A. Carraway,et al.  Reversible Disruption of Cell-Matrix and Cell-Cell Interactions by Overexpression of Sialomucin Complex* , 1997, The Journal of Biological Chemistry.

[28]  M. Cummings,et al.  Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours , 1997, The Journal of pathology.

[29]  M. Nieman,et al.  Cadherins Promote Skeletal Muscle Differentiation in Three-dimensional Cultures , 1997, The Journal of cell biology.

[30]  J. Wesseling,et al.  A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. , 1996, Molecular biology of the cell.

[31]  C. Balagué,et al.  In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. , 1995, Gastroenterology.

[32]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[33]  G. Edelman,et al.  Topology of cell adhesion molecules. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[35]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[36]  S. Gendler,et al.  Epithelial mucin genes. , 1995, Annual review of physiology.

[37]  N. Dubrawsky.  Cancer statistics , 2022 .